TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
18 hedge funds and large institutions have $2.14M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
20% more funds holding
Funds holding: 15 → 18 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital invested
Capital invested by funds: $2.81M → $2.14M (-$667K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$233K |
| 2 |
Two Sigma Investments
New York
|
+$104K |
| 3 |
JP Morgan Chase
New York
|
+$99K |
| 4 |
Millennium Management
New York
|
+$84K |
| 5 |
DY
Dowling & Yahnke
San Diego,
California
|
+$43.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$174K |
| 2 |
PCM
Puissance Capital Management
New York
|
-$168K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$25K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$7.2K |
TCON Hedge Fund Activity: Q1 2020 in Review
18 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q1 2020, worth a combined $2.14M — down 24% from $2.81M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new TCON positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $233K. The largest seller was 683 Capital Management, cutting an estimated $174K.
- 18 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q1 2020, up from 15 in Q4 2019.
- Funds reported $2.14M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 24% quarter-over-quarter.
- 7 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 3 closed out, a net change of +4 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Renaissance Technologies, an estimated $233K added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was 683 Capital Management, an estimated $174K sold.
Based on aggregated 13F filings for Q1 2020.